ATBECHDEDKESFRGBGRITLILUNLSEMCPTIESILTLVFIROMKCYALTRBGCZEEHUPLSK..HRIS..MTNORS..SM..................JBDM Ver 2.0.16 (1th of February 2022) - 2999001/03733163CORRECTED EUROPEAN PATENT SPECIFICATIONB8B120220928W173deBibliographieenBibliographyfrBibliographieEP20179085.42018041320200609enenen201762485355 P20170413US20171568832020170828USPCT/US2017/04889020170828WO2022092820223920201104202045202206082022232022010320220928202239A61K 9/00 20060101AFI20200904BHEP A61K 9/48 20060101ALI20200904BHEP A61K 31/198 20060101ALI20200904BHEP A61P 35/00 20060101ALI20200904BHEP A61P 35/02 20060101ALI20200904BHEP A61K 31/196 20060101ALI20200904BHEP A61K 47/10 20170101ALI20200904BHEP A61K 9/0019 20130101 LI20181017BHEP A61K 9/4866 20130101 LI20171215BHEP A61K 31/198 20130101 LI20171215BHEP A61K 47/10 20130101 LI20181016BHEP A61K 31/196 20130101 FI20181016BHEP A61P 35/00 20180101 LI20180613BHEP A61P 35/02 20180101 LI20180613BHEP de(E)-2,4,6-TRIMETHOXYSTYRYL-3-[(CARBOXYMETHYL)AMINO]-4-METHOXYBENZYLSULPHONE ZUR VERWENDUNG IN DER BEHANDLUNG VON ZUSTÄNDEN RESULTIEREND AUS ABNORMALER ZELLPROLIFERATIONen(E)-2,4,6-TRIMETHOXYSTYRYL-3-[(CARBOXYMETHYL)AMINO]-4-METHOXYBENZYLSULPHONE FOR USE IN A METHOD OF TREATING CONDITIONS MEDIATED BY ABNORMAL CELL PROLIFERATIONfr(E)-2,4,6-TRIMETHOXYSTYRYL-3-[(CARBOXYMETHYL)AMINO]-4-METHOXYBENZYLSULPHONE POUR L'UTILISATION POUR LE TRAITEMENT DES CONDITIONS QUI RESULTENT DE LA PROLIFERATION CELLULAIRE ANORMALEUS-A1- 2015 313 859RAZA AZRA ET AL: "Oral Rigosertib (ON 01910.Na) Treatment Produces A Encouraging Rate Of Transfusion Independence In Lower Risk Myelodysplastic Syndromes (MDS) Patients; A Genomic Methylation Profile Is Associated With Responses", BIOSIS, BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US, 1 November 2013 (2013-11-01), XP002788716,NAVADA SHYAMALA C ET AL: "Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS): Results from a Phase II Study", BIOSIS, BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US, 2 December 2016 (2016-12-02), XP002788717,NAVADA SHYAMALA C ET AL: "A Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS)", BIOSIS, BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US, 1 December 2015 (2015-12-01), XP002788718,RAMI S. KOMROKJI ET AL: "Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes", BRITISH JOURNAL OF HAEMATOLOGY, vol. 162, no. 4, 21 June 2013 (2013-06-21) , pages 517-524, XP055483608, GB ISSN: 0007-1048, DOI: 10.1111/bjh.1243618718572.3360947120180413MANIAR, Manoj46750 Sentinel DriveFremont, CA California 94539USOnconova Therapeutics, Inc.101940640P120106EP1012 Penns TrailNewtown, PA 18940USV.O.101551773P.O. Box 879302508 DH Den HaagNLALATBEBGCHCYCZDEDKEEESFIFRGBGRHRHUIEISITLILTLULVMCMKMTNLNOPLPTRORSSESISKSMTR